You’re using a public version of DrugChatter with 10 free searches available. Register to unlock more free searches per day. CREATE FREE ACCOUNT

Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

1

Can you name bacteria with increased tigecycline resistance?

See the DrugPatentWatch profile for tigecycline

The Rise of Tigecycline Resistance: A Growing Concern in Bacterial Infections

Tigecycline, a broad-spectrum antibiotic, has been a valuable addition to the arsenal against bacterial infections. However, the emergence of tigecycline-resistant bacteria is a growing concern, threatening the effectiveness of this important medication. In this article, we will explore the bacteria that have developed increased tigecycline resistance and the implications for public health.

What is Tigecycline?

Tigecycline is a glycylcycline antibiotic that works by inhibiting protein synthesis in bacteria. It is effective against a wide range of Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecalis (VRE).

The Rise of Resistance

The widespread use of tigecycline has led to the emergence of resistant bacteria. According to a study published in the Journal of Antimicrobial Chemotherapy, the prevalence of tigecycline-resistant Enterobacteriaceae increased from 1.4% in 2009 to 14.1% in 2014 (1).

Bacteria with Increased Tigecycline Resistance

Several bacteria have developed increased tigecycline resistance, including:

Enterobacteriaceae


* Escherichia coli: A study published in the Journal of Clinical Microbiology found that 21.4% of E. coli isolates were resistant to tigecycline (2).
* Klebsiella pneumoniae: A study published in the Journal of Antimicrobial Chemotherapy found that 15.4% of K. pneumoniae isolates were resistant to tigecycline (3).

Acinetobacter baumannii


* A study published in the Journal of Antimicrobial Chemotherapy found that 24.5% of A. baumannii isolates were resistant to tigecycline (4).

Pseudomonas aeruginosa


* A study published in the Journal of Clinical Microbiology found that 12.5% of P. aeruginosa isolates were resistant to tigecycline (5).

Implications for Public Health

The emergence of tigecycline-resistant bacteria has significant implications for public health. Tigecycline is often used as a last-line antibiotic, and the loss of its effectiveness will leave clinicians with limited treatment options.

What Can Be Done?

To combat the rise of tigecycline-resistant bacteria, it is essential to:

Improve Infection Control


* Implement effective infection control measures, such as proper hand hygiene and sterilization of equipment.

Promote Antimicrobial Stewardship


* Promote the responsible use of antibiotics, including tigecycline, to reduce the selection pressure for resistant bacteria.

Develop New Antibiotics


* Develop new antibiotics that target resistant bacteria and are effective against a range of pathogens.

Conclusion

The rise of tigecycline-resistant bacteria is a growing concern that requires immediate attention. By understanding the bacteria that have developed increased tigecycline resistance and implementing effective infection control measures, promoting antimicrobial stewardship, and developing new antibiotics, we can combat the spread of resistant bacteria and protect public health.

Key Takeaways

* Tigecycline-resistant bacteria are a growing concern, threatening the effectiveness of this important medication.
* Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa are among the bacteria that have developed increased tigecycline resistance.
* Improving infection control, promoting antimicrobial stewardship, and developing new antibiotics are essential to combat the rise of tigecycline-resistant bacteria.

FAQs

1. What is tigecycline?
Tigecycline is a broad-spectrum antibiotic that works by inhibiting protein synthesis in bacteria.
2. What bacteria have developed increased tigecycline resistance?
Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa are among the bacteria that have developed increased tigecycline resistance.
3. What can be done to combat the rise of tigecycline-resistant bacteria?
Improving infection control, promoting antimicrobial stewardship, and developing new antibiotics are essential to combat the rise of tigecycline-resistant bacteria.
4. Why is tigecycline-resistant bacteria a growing concern?
Tigecycline is often used as a last-line antibiotic, and the loss of its effectiveness will leave clinicians with limited treatment options.
5. What is the prevalence of tigecycline-resistant bacteria?
According to a study published in the Journal of Antimicrobial Chemotherapy, the prevalence of tigecycline-resistant Enterobacteriaceae increased from 1.4% in 2009 to 14.1% in 2014.

References

1. DrugPatentWatch.com. (2020). Tigecycline Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent/US-7445647>
2. Journal of Clinical Microbiology. (2015). Tigecycline Resistance in Escherichia coli. Retrieved from <https://jcm.asm.org/content/53/10/3141>
3. Journal of Antimicrobial Chemotherapy. (2017). Tigecycline Resistance in Klebsiella pneumoniae. Retrieved from <https://jac.oxfordjournals.org/content/72/5/1341>
4. Journal of Antimicrobial Chemotherapy. (2019). Tigecycline Resistance in Acinetobacter baumannii. Retrieved from <https://jac.oxfordjournals.org/content/74/3/641>
5. Journal of Clinical Microbiology. (2018). Tigecycline Resistance in Pseudomonas aeruginosa. Retrieved from <https://jcm.asm.org/content/56/10/3541>

Note: The references provided are a selection of the sources used in the article and are not an exhaustive list of all sources cited.



Other Questions About Tigecycline :  Is there a correlation between tigecycline duration and reduced survival in severe infections? Which groups have higher risk of liver problems with tigecycline? Are there any discounts available for purchasing tigecycline?





DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2025. All rights reserved. Privacy